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Introduction: SARS-CoV2 is a worldwide health threat, which has as its main 
risk group patients with head and neck cancer. In the time being and in the chance 
of an emerging second wave of infection, a new protocol based on when to treat 
patients with head and neck cancer must be implemented. Aim: Reporting the 
handling protocols for patients with head and neck cancer, facilitating the 
clinician's decision in the pandemic scenario. Materials and Methods: A 
bibliographic search was performed in PubMed. A search strategy with 
descriptors was applied to the database, aiming at reaching scientific articles. 
The articles reached in such database had their titles and abstracts read in search 
for the adequacy to the objective proposed. Only scientific articles published 
between December 1st 2019, and July 10th 2020, were chosen. There was no 
 
 
restriction either on country or language. Literature review: New protocols were 
created based on the type and stage of cancer, classifying them in order to 
identify the ideal time to operate safely. Thus, the protocol has levels from initial 
to advanced, where the initial level comprises benign neoplasms, skin cancers 
smaller than 2 mm and cases in asymptomatic early stages, and the advanced 
level comprises malignant, aggressive neoplasms, with painful symptoms and/or 
that are compromising the other systems and organs. Conclusion: It is 
necessary to follow the detailed care protocol to guide the progress of head and 
neck cancer services, by operating patients immediately or postponing surgery, 
depending on the case and seriousness. 
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RESUMO 
Introdução: O novo coronavirus SARS-CoV2 é uma ameaça de saúde mundial 
que tem como um de seus principais grupo de risco os pacientes com câncer de 
cabeça e pescoço. Na atual conjuntura e em caso de uma segunda onda de 
infecção, há necessidade de um novo protocolo de quando tratar esses 
pacientes. Objetivo: Relatar os protocolos de manejo e atendimento dos 
pacientes com câncer de cabeça e pescoço, facilitando a decisão do clínico no 
cenário de pandemia. Materiais e Métodos: Uma busca bibliográfica foi 
realizada no PubMed. Uma estratégia de busca com descritores foi aplicada, 
onde os artigos alcançados tiveram seus títulos e resumos lidos em busca da 
adequação ao objetivo proposto. Foram selecionados artigos científicos 
publicados entre 1 de dezembro de 2019 e 10 de julho de 2020, sem restrição 
de país ou idioma. Revisão da literatura: Novos protocolos foram criados 
baseados no tipo e estágio de câncer, classificando-os para saber o momento 
ideal de intervir com segurança. O protocolo se dá em níveis de inicial ao 
avançado onde o inicial compreende as neoplasias benignas, ou seja, cânceres 
de pele menores de 2 mm e casos em estágios iniciais assintomáticos, e o nível 
avançado compreende neoplasias malignas, agressivas, com sintomatologia 
dolorosa e/ou que estejam comprometendo os outros sistemas e órgãos. 
 
 
Conclusão: Há necessidade de seguir o protocolo de atendimento detalhado 
que norteie o andamento dos serviços oncológicos de cabeça e pescoço, 
atendendo os pacientes imediatamente ou adiando o tratamento dependendo do 
caso e severidade. 




SARS-CoV-2 is an emerging virus that causes coronavirus disease as 
from 2019 (COVID-19), which on March 11, 2020, it was characterized by World 
Health Organization (WHO) as a pandemic, provoking a deficit in the health 
system, and, thus, the reduction of vacancies in the Intensive Care Units (ICUs). 
Despite all efforts, the disease has caused many deaths directly, due to severe 
acute respiratory syndrome (SARS), and indirectly due to lack of care and 
diagnosis of other diseases, such as cancer patients1-5. 
Actually, there is doubt as to whether there is benefit in clinical care during 
the pandemic, since the response to the virus may interact with the 
pathophysiology of cancer, or when care is being provided. Head and neck 
cancer is among the most common types of cancer in Brazil, whose mortality rate 
is 40% to 50% when untreated, which can increase if there is concomitant 
contamination by SARS-CoV-2, or due to absence of diagnosis or treatment6,7. 
The interaction between SARS-CoV-2 and head and neck cancers is also 
given by the cytokines of the Interferon family (IFN). SARS-CoV-2 transcribes 
viral proteins into the cytosol of the infected cell, which block the factors 
necessary for the production of IFNs. IFNs, on the other hand, play an active role 
in combating head and neck cancers, by increasing the antigenicity of tumor cells, 
through positive regulation of the Major Histocompatibility Complex (MHC), as 
well as by inhibiting cell proliferation or by inducing cell apoptosis with cancer8-11. 
In view of the current pandemic and the risk of a second wave of infection, 
a fact that is occurring in countries that have had premature contact with the virus, 
a new safe care protocol for cancer patients has become necessary, based on 
 
 
their types, stages and symptomatology, since these patients are in the risk group 
for the new coronavirus and because hospitals are now potential sites for viral 
transmission. Thus, the objective of this work is to report the management and 
care protocols of patients with head and neck cancer, facilitating the dentist's 
decision in this current pandemic scenario in Brazil or should there be a second 
wave of infection. 
 
MATERIALS AND METHODS  
  A bibliographic search was performed at PubMed. In the cited database, 
a search strategy with descriptors for access to scientific articles was applied: 
“Coronavirus Infections” [DeCS terms] AND “Head and Neck Neoplasms” [DeCS 
terms] AND "Betacoronavirus" [DeCS terms]. The articles reached in such 
database had their titles and abstracts read in search for adaptation to the 
proposed objective. Only scientific articles published between 1 December, 2019, 
and 10 July, 2020, were selected. There were no restrictions, either on country 
or on language. The research aimed at the analysis, comparison and synthesis 
of data to reach the final objective. 
  The selection of the literature was made by systematically eliminating 
articles that did not have an intimate relation to the theme. Finally, 8 articles were 
included, based on these pre-established criteria, for which we proceeded with 




 According to the studies6,7,12, the current scenario of the SARS-CoV-2 
pandemic has raised doubts about how to deal with head and neck cancer. These 
doubts were raised based on different points of perspective. From the point of 
view of the patient’s, the type and stage of cancer, symptoms, age, systems 
affected by cancer or other systemic diseases must be taken into account. From 
the point of view of health professionals, care in the hospital environment and 
possible exposure of the debilitated patient to the virus should be considered, 
 
 
assuring if they have adequate personal protective equipment (PPE) to treat the 
cancer patient and training in the handling of COVID19+ patients. Finally, from 
the point of view of hospitals, questioning if there are exclusive sectors for cancer 
patients and/or for COVID19+ patients, making sure if there are ICU vacancies 
for cancer patients in the pre and postoperative period, and if they have a blood 
bank with adequate stock, telehealth services for postoperative follow-up. The 
amount of generation of aerosols in surgical cases, since this is a path of high 
spread of SARS-CoV-2, should be considered because it promotes the 
suspension of the virus in the air for up to 3 hours. 
 Thus, a new analysis needs to be performed, so that the care of patients 
with head and neck cancer continues safely and effectively. If the lack of 
diagnosis or delay in the treatment of patients with head and neck cancer can 
compromise the prognosis and can lead to death. Furthermore, the exposure of 
the cancer patient in a hospital environment during the pandemic period can 
accelerate the pathophysiology of the disease, since virus actions in the cell can 
interfere with the host's defense mechanisms against cancer9. Indeed, the non-
structural proteins (ORF6 and ORF8) of SARS-CoV-2 when transcribes into the 
cytoplasm of the infected cell, they inhibit the entry of two transcription factors 
(TRAF3 and TRAF6) responsible for the transcription of mRNA and increases in 
interferon levels. IFNs are directly related to a TH1-type immune response that 
promotes an effective response against viruses (especially the new coronavirus), 
and also generate an inflammatory response that inhibits tumor growth, with 
increased TNF expression and decreased growth factors13,14. It is important to 
mention that the cells infected by SARS-CoV-2 are ECA2 + and TMPRSS2 +, 
which mostly comprise epithelial cells9. Also, that virus can enter the organisms 
through the oral cavity, where a large number of infected epithelial cells and 
regions of different types of head and neck cancer are observed. Since SARS-
CoV-2 infection and IFN production in this region have a dependence on time 
and viral load, and that the different types of cancer have particularity and 
severity, it is important to establish a time-based care protocol, which does not 
compromise the prognosis of both pathologies in comorbidity13-15.  
 
 
 Based on this, Day et al.12 classified patients, health professionals, surgery 
and post-surgery into three levels: low, medium and high risk. The low-risk stage 
includes patients who underwent self-quarantine for 14 days before the surgical 
procedure, asymptomatic patients with a negative result for the SARS-CoV-2 test 
performed 0 to 2 days before the visit. In relation to professionals, asymptomatic 
professionals with negative tests, routinely performed are classified as low risk. 
Short-term surgeries without aerosol generating procedures (AGPs), 
cauterization and suction procedures in upper aerodigestive tract (UADT) surgery 
are also included at this level. The low-risk post-surgical period must have no 
AGPs and the need for hospitalization or at least a short duration. The medium 
risk level does not apply to patients or professionals, being composed of 
procedures with limited AGP and without UADT, added to post-surgical 
procedures with frequent aerosol generating procedures and with brief hospital 
admission. The high level includes patients who cannot perform self-quarantine, 
with inconclusive symptoms for Covid-19 and without the possibility of testing for 
SARS-CoV-2. Professionals at this level have Covid-19 symptoms and/or have 
inadequate PPEs and are not routinely tested. In this stage, surgeries and 
postoperative periods with intense AGPs, UADT and need for hospitalization are 
also included. 
 More broadly, in relation to the patient, Ranasinghe et al.16, Topf et al.17 
and Morrison et al.18 used a classification emphasizing each pathology (table 1). 
At the initial level, there are benign neoplasms and skin cancer are smaller than 
2 centimeters, except for melanoma, which must be monitored and, if possible, 
have the surgical procedure postponed. Non-melanoma skin cancers larger than 
2 centimeters, tumors of low malignancy and lesions requiring cervical lymph 
node biopsy are classified as intermediate level. The advanced level consists of 
neoplasms with high malignancy in an advanced stage, melanoma, thyroid 
cancer, squamous cell carcinoma, direct laryngoscopy, cases associated with 
human papillomavirus (HPV) and cases that compromise the airways. In this 
classification, only patients with advanced level demands should undergo surgery 
immediately, patients who do not fit this classification should have the procedure 
 
 
discussed with a multidisciplinary team assessing risks. All procedures were 
performed after preoperative testing and monitoring. The remainder was followed 
up through telemedicine consultations, aiming at lower risks of patient-
professional contamination and vice versa.  
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 All studies show preoperative testing as an unreliable factor, given the 
evidence of false negatives ones. Another bias is the preoperative quarantine, 
given that each patient has particularities that influence the level of social isolation 
possible for their needs. It is also worth mentioning that the protocol must be 
applied during periods of restricted health care, where the specific region has a 
high rate of contamination, a reduction in the number of ICU vacancies and a 
positive population for SARS-CoV2 in an increasing trend. 
 
CONCLUSION 
 Facing the Covid-19 pandemic, health care protocols need adaptations, 
especially head and neck cancer ones. Taking into account the results obtained 
by this work, we conclude that there is a need to follow the detailed care protocol 
that guides the progress of head and neck cancer services, assisting patients 
immediately or postponing treatment, depending on the case and severity. 
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